PMID- 25026924
OWN - NLM
STAT- MEDLINE
DCOM- 20151125
LR  - 20150205
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
VI  - 52
IP  - 1
DP  - 2015 Feb
TI  - Serum fructosamine and risk of type 2 diabetes mellitus among middle-age Finnish 
      men: a 23-year population-based prospective study.
PG  - 161-6
LID - 10.1007/s00592-014-0625-8 [doi]
AB  - The aim of this study was to determine whether serum fructosamine is associated 
      with the risk of type 2 diabetes mellitus (T2DM) in a cohort of middle-age 
      Finnish men. Fructosamine and other cardiometabolic risk factors were measured in 
      a sample of 2,520 subjects from the population-based Kuopio Ischemic Heart 
      Disease study. Associations between baseline fructosamine levels and risk of T2DM 
      involved Cox-regression analyses, progressively adjusted for potential 
      confounders and mediators. Mean baseline age and fructosamine levels were 53 
      years and 267 micromol/L, respectively. During a median follow-up of 23 years 
      (interquartile range 18-25 years), 153 (6.1 %) new cases of T2DM were recorded. 
      We observed an approximately "J-shaped" association between fructosamine values 
      and T2DM risk, with a nadir at about 250 micromol/L. In subjects with fructosamine 
      >/=250 micromol/L, the hazard ratios per 1 standard deviation (28 micromol/L) higher 
      fructosamine levels resulted 1.20 (95 % CI 1.00-1.44; p = 0.046) in a model 
      adjusted for age, body mass index, systolic blood pressure, serum high-density 
      lipoprotein-cholesterol and family history T2DM. This association did not 
      materially change upon further adjustment for C-reactive protein, physical 
      activity, serum triglyceride and insulin resistance. However, no association was 
      found when adjusting for baseline fasting plasma glucose (FPG). In this cohort of 
      middle-age Finnish men, we found a "J-shaped" relationship between fructosamine 
      and risk of T2DM, with a higher risk in subjects with baseline levels of 
      fructosamine >/=250 micromol/L. Such an increased risk, however, was not independent 
      from baseline FPG levels.
FAU - Zaccardi, Francesco
AU  - Zaccardi F
AD  - Internal Medicine and Diabetes Care Unit, Catholic University, Rome, Italy, 
      frazac@fastwebnet.it.
FAU - Kurl, Sudhir
AU  - Kurl S
FAU - Pitocco, Dario
AU  - Pitocco D
FAU - Ronkainen, Kimmo
AU  - Ronkainen K
FAU - Laukkanen, Jari A
AU  - Laukkanen JA
LA  - eng
PT  - Journal Article
DEP - 20140716
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
RN  - 0 (Blood Glucose)
RN  - 0 (Lipoproteins, HDL)
RN  - 4429-04-3 (Fructosamine)
RN  - 9007-41-4 (C-Reactive Protein)
SB  - IM
MH  - Adult
MH  - Blood Glucose/metabolism
MH  - C-Reactive Protein/metabolism
MH  - Diabetes Mellitus, Type 2/*blood/epidemiology
MH  - Finland/epidemiology
MH  - Fructosamine/*blood
MH  - Humans
MH  - Lipoproteins, HDL/metabolism
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
EDAT- 2014/07/17 06:00
MHDA- 2015/12/15 06:00
CRDT- 2014/07/17 06:00
PHST- 2014/04/29 00:00 [received]
PHST- 2014/06/30 00:00 [accepted]
PHST- 2014/07/17 06:00 [entrez]
PHST- 2014/07/17 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.1007/s00592-014-0625-8 [doi]
PST - ppublish
SO  - Acta Diabetol. 2015 Feb;52(1):161-6. doi: 10.1007/s00592-014-0625-8. Epub 2014 
      Jul 16.